Nov 10 (Reuters) - AN2 Therapeutics Inc ANTX.O:
AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)
AN2 THERAPEUTICS: GATES FOUNDATION WILL PROVIDE THIRD YEAR OF FUNDING TO SUPPORT AN2'S WORK WITHIN COLLABORATION
Source text: ID:nBwb9X3F1a
Further company coverage: ANTX.O
((reuters.briefs@thomsonreuters.com;))